Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    86,062.85
    +4,838.72 (+5.96%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Today's Research Reports on Microbix Biosystems, GeneNews, Neovasc and Trillium Therapeutics

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Microbix Biosystems Inc.
https://rdinvesting.com/news/?ticker=MBX.TO

GeneNews Limited
https://rdinvesting.com/news/?ticker=GEN.TO

Neovasc Inc.
https://rdinvesting.com/news/?ticker=NVCN.TO

Trillium Therapeutics Inc.
https://rdinvesting.com/news/?ticker=TRIL.TO

Microbix Biosystems' stock jumped 11.32% Wednesday, to close the day at $0.295. The stock recorded a trading volume of 115,900 shares, which was above its three months average volume of 44,284 shares. In the last year, Microbix Biosystems' shares have traded in a range of 0.25 - 0.40. The share price has gained 18.00% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.288 is below its 200-day moving average of $0.289. Shares of Microbix Biosystems have fallen approximately 3.23 percent year-to-date.

ADVERTISEMENT

Access RDI's Microbix Biosystems Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MBX.TO

On Wednesday, shares of GeneNews recorded a trading volume of 19,635 shares, which was below the three months average volume of 167,828 shares. The stock ended the day 12.50% higher at 0.09. The share price has gained 28.57% from its 52-week low with a 52-week trading range of 0.07 - 0.24. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.08 is below its 200-day moving average of $0.12. Shares of GeneNews have fallen approximately 65.22 percent year-to-date.

Access RDI's GeneNews Limited Research Report at:
https://rdinvesting.com/news/?ticker=GEN.TO

Neovasc's stock jumped 20.00% Wednesday, to close the day at $0.06. The stock recorded a trading volume of 903,611 shares, which was below its three months average volume of 5,835,460 shares. In the last year, Neovasc's shares have traded in a range of 0.04 - 2.32. The share price has gained 50.00% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.05 is below its 200-day moving average of $0.30. Shares of Neovasc have fallen approximately 92 percent year-to-date.

Access RDI's Neovasc Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVCN.TO

On Wednesday, shares of Trillium Therapeutics recorded a trading volume of 3,526 shares, which was below the three months average volume of 5,929 shares. The stock ended the day 5.35% lower at 7.79. The share price has gained 48.10% from its 52-week low with a 52-week trading range of 5.26 - 16.80. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $8.03 is below its 200-day moving average of $9.02. Shares of Trillium Therapeutics have fallen approximately 14.4 percent year-to-date.

Access RDI's Trillium Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TRIL.TO

Our Actionable Research on Microbix Biosystems Inc. (TSX:MBX.TO) and GeneNews Limited (TSX:GEN.TO) and Neovasc Inc. (TSX:NVCN.TO) and Trillium Therapeutics Inc. (TSX:TRIL.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com